{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:41:48Z","timestamp":1791297708533,"version":"4.1.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bpgastro.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.bpg.2012.12.002","type":"journal-article","created":{"date-parts":[[2013,4,10]],"date-time":"2013-04-10T09:58:40Z","timestamp":1365587920000},"page":"755-773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Neuroendocrine tumours of the small intestine"],"prefix":"10.1016","volume":"26","author":[{"given":"Jonathan","family":"Strosberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2012.12.002_bib1","series-title":"\u00dcber diffuse endocrine epitheliale Organe","author":"Feyrter","year":"1938"},{"issue":"2","key":"10.1016\/j.bpg.2012.12.002_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000096997","article-title":"Evolution of the diffuse neuroendocrine system\u2013clear cells and cloudy origins","volume":"84","author":"Modlin","year":"2006","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.bpg.2012.12.002_bib3","first-page":"425","article-title":"Karzinoide Tumoren des D\u00fcnndarms","volume":"1","author":"Oberndorfer","year":"1907","journal-title":"Frankf Z Pathol"},{"key":"10.1016\/j.bpg.2012.12.002_bib4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(63)90951-6","article-title":"The classification of carcinoid tum ours","volume":"1","author":"Williams","year":"1963","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bpg.2012.12.002_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/01.sla.0000129342.67174.67","article-title":"Updated population-based review of carcinoid tumors","volume":"240","author":"Maggard","year":"2004","journal-title":"Ann Surg"},{"issue":"18","key":"10.1016\/j.bpg.2012.12.002_bib6","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"44","key":"10.1016\/j.bpg.2012.12.002_bib7","doi-asserted-by":"crossref","first-page":"7028","DOI":"10.3748\/wjg.v11.i44.7028","article-title":"Upper gastrointestinal carcinoid tumors incidentally found by endoscopic examinations","volume":"11","author":"Chuah","year":"2005","journal-title":"World J Gastroenterol"},{"issue":"8","key":"10.1016\/j.bpg.2012.12.002_bib8","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/1097-0142(20011015)92:8<2204::AID-CNCR1564>3.0.CO;2-R","article-title":"Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden","volume":"92","author":"Hemminki","year":"2001","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bpg.2012.12.002_bib9","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"5-decade analysis of 13,715 carcinoid tumors","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.bpg.2012.12.002_bib10","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.1987.5.10.1502","article-title":"Karnofsky memorial lecture. An odyssey in the land of small tumors","volume":"5","author":"Moertel","year":"1987","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bpg.2012.12.002_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/BF01658532","article-title":"Surgical treatment of mid-gut carcinoid tumors","volume":"14","author":"Makridis","year":"1990","journal-title":"World J Surg"},{"key":"10.1016\/j.bpg.2012.12.002_bib12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/1097-0142(196109\/10)14:5<901::AID-CNCR2820140502>3.0.CO;2-Q","article-title":"Life history of the carcinoid tumor of the small intestine","volume":"14","author":"Moertel","year":"1961","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.bpg.2012.12.002_bib13","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJM199903183401107","article-title":"Carcinoid tumors","volume":"340","author":"Kulke","year":"1999","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bpg.2012.12.002_bib14","first-page":"720","article-title":"Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids","volume":"90","author":"Eckhauser","year":"1981","journal-title":"Surgery"},{"issue":"3","key":"10.1016\/j.bpg.2012.12.002_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/jso.20179","article-title":"Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract","volume":"89","author":"Rorstad","year":"2005","journal-title":"J Surg Oncol"},{"issue":"4","key":"10.1016\/j.bpg.2012.12.002_bib16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1159\/000197899","article-title":"Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut","volume":"89","author":"Strosberg","year":"2009","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.bpg.2012.12.002_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2007.02.034","article-title":"Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases","volume":"106","author":"Strosberg","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.bpg.2012.12.002_bib18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0002-8703(54)90152-0","volume":"47","author":"Thorson","year":"1954","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.bpg.2012.12.002_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.CIR.12.1.1","article-title":"The syndrome of carcinoid and acquired valve lesions of the right side of the heart","volume":"12","author":"Bean","year":"1955","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.bpg.2012.12.002_bib20","first-page":"50","article-title":"Detection of 5-hydroxytryptamine in carcinoid metastases","volume":"221","author":"Lembeck","year":"1954","journal-title":"Naunyn Schmiedebergs Arch Exp Pathol Pharmakol"},{"issue":"4306","key":"10.1016\/j.bpg.2012.12.002_bib21","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/169800b0","article-title":"Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine","volume":"169","author":"Erspamer","year":"1952","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bpg.2012.12.002_bib22","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/MPA.0b013e3181bc0e77","article-title":"Biochemical testing for neuroendocrine tumors","volume":"38","author":"Vinik","year":"2009","journal-title":"Pancreas"},{"issue":"4","key":"10.1016\/j.bpg.2012.12.002_bib23","first-page":"637","article-title":"The malignant carcinoid syndrome","volume":"137","author":"Davis","year":"1973","journal-title":"Surg Gynecol Obstet"},{"issue":"15","key":"10.1016\/j.bpg.2012.12.002_bib24","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1056\/NEJM199310073291503","article-title":"Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea","volume":"329","author":"von der Ohe","year":"1993","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bpg.2012.12.002_bib25","first-page":"237","article-title":"Carcinoid tumors and syndrome","volume":"14","author":"Feldman","year":"1987","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.bpg.2012.12.002_bib26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1530\/EJE-08-0196","article-title":"Tachykinins in endocrine tumors and the carcinoid syndrome","volume":"159","author":"Cunningham","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.bpg.2012.12.002_bib27","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/0016-5085(95)90447-6","article-title":"Serotonin, catecholamines, and spontaneous midgut carcinoid flush: plasma studies from flushing and nonflushing sites","volume":"108","author":"Matuchansky","year":"1995","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.bpg.2012.12.002_bib28","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2133.1974.tb06451.x","article-title":"Blood prostaglandin activity associated with noradrenaline-provoked flush in the carcinoid syndrome","volume":"90","author":"Smith","year":"1974","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bpg.2012.12.002_bib29","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1749-6632.1994.tb17296.x","article-title":"Metastatic carcinoid tumors and the malignant carcinoid syndrome","volume":"733","author":"Kvols","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bpg.2012.12.002_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.1964.03860070072004","article-title":"The carcinoid crisis","volume":"114","author":"Kahil","year":"1964","journal-title":"Arch Intern Med"},{"issue":"19","key":"10.1016\/j.bpg.2012.12.002_bib31","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1056\/NEJM198511073131916","article-title":"Rapid reversal of carcinoid crisis with a somatostatin analogue","volume":"313","author":"Kvols","year":"1985","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bpg.2012.12.002_bib32","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/01.CIR.92.4.790","article-title":"Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography","volume":"92","author":"Robiolio","year":"1995","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.bpg.2012.12.002_bib33","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1161\/01.CIR.77.2.264","article-title":"Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities","volume":"77","author":"Lundin","year":"1988","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.bpg.2012.12.002_bib34","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/cncr.11226","article-title":"Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor","volume":"97","author":"Zuetenhorst","year":"2003","journal-title":"Cancer"},{"issue":"12 Suppl. 1","key":"10.1016\/j.bpg.2012.12.002_bib35","doi-asserted-by":"crossref","first-page":"I36","DOI":"10.1161\/hc37t1.094898","article-title":"Surgical management of left-sided carcinoid heart disease","volume":"104","author":"Connolly","year":"2001","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.bpg.2012.12.002_bib36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000335629","article-title":"ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas","volume":"95","author":"Pape","year":"2012","journal-title":"Neuroendocrinology"},{"issue":"6","key":"10.1016\/j.bpg.2012.12.002_bib37","doi-asserted-by":"crossref","first-page":"724","DOI":"10.6004\/jnccn.2012.0075","article-title":"Neuroendocrine tumors","volume":"10","author":"Kulke","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.bpg.2012.12.002_bib38","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.humpath.2009.01.010","article-title":"Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Strosberg","year":"2009","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/j.bpg.2012.12.002_bib39","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0b013e3181ec124e","article-title":"The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems","volume":"39","author":"Klimstra","year":"2010","journal-title":"Pancreas"},{"issue":"4","key":"10.1016\/j.bpg.2012.12.002_bib40","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1200\/JCO.2012.44.5924","article-title":"Prognostic validity of the American Joint Committee on Cancer (AJCC) staging classification for midgut neuroendocrine tumros","volume":"31","author":"Strosberg","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bpg.2012.12.002_bib41","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00428-007-0452-1","article-title":"TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system","volume":"451","author":"Rindi","year":"2007","journal-title":"Virchows Arch"},{"key":"10.1016\/j.bpg.2012.12.002_bib42","series-title":"AJCC cancer staging manual","year":"2010"},{"issue":"15","key":"10.1016\/j.bpg.2012.12.002_bib43","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1002\/cncr.25855","article-title":"Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome","volume":"117","author":"Jann","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bpg.2012.12.002_bib44","first-page":"33","article-title":"The carcinoid syndrome: a treatable malignant disease","volume":"2","author":"Kvols","year":"1988","journal-title":"Oncology (Huntingt)"},{"key":"10.1016\/j.bpg.2012.12.002_bib45","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/0002-9610(64)90172-2","article-title":"Carcinoid tumors of the rectum","volume":"107","author":"Caldarola","year":"1964","journal-title":"Am J Surg"},{"issue":"Pt 3","key":"10.1016\/j.bpg.2012.12.002_bib46","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1258\/000456307780480936","article-title":"Monitoring the treatment of carcinoid disease using blood serotonin and plasma 5-hydroxyindoleacetic acid: three case examples","volume":"44","author":"Allen","year":"2007","journal-title":"Ann Clin Biochem"},{"issue":"Pt 6","key":"10.1016\/j.bpg.2012.12.002_bib47","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/000456320203900605","article-title":"Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease","volume":"39","author":"Carling","year":"2002","journal-title":"Ann Clin Biochem"},{"issue":"15","key":"10.1016\/j.bpg.2012.12.002_bib48","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1200\/JCO.2006.10.1535","article-title":"Chromogranin A: is it a useful marker of neuroendocrine tumors?","volume":"25","author":"Campana","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bpg.2012.12.002_bib49","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.regpep.2009.11.013","article-title":"Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors","volume":"165","author":"Conlon","year":"2010","journal-title":"Regul Pept"},{"issue":"9","key":"10.1016\/j.bpg.2012.12.002_bib50","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1046\/j.1365-2362.2001.00890.x","article-title":"Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy","volume":"31","author":"Sanduleanu","year":"2001","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"10.1016\/j.bpg.2012.12.002_bib51","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1245\/s10434-006-9148-z","article-title":"Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors","volume":"14","author":"Jensen","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.bpg.2012.12.002_bib52","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1210\/jc.2011-0666","article-title":"Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus","volume":"96","author":"Yao","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.bpg.2012.12.002_bib53","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8","article-title":"Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors","volume":"86","author":"Bajetta","year":"1999","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bpg.2012.12.002_bib54","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MPA.0b013e318249a92a","article-title":"Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?","volume":"41","author":"Ito","year":"2012","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.bpg.2012.12.002_bib55","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1148\/radiology.206.1.9423664","article-title":"Carcinoid metastases to the liver: role of triple-phase helical CT","volume":"206","author":"Paulson","year":"1998","journal-title":"Radiology"},{"issue":"10","key":"10.1016\/j.bpg.2012.12.002_bib56","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1007\/s10620-011-1773-0","article-title":"CT-enterography may identify small bowel tumors not detected by capsule endoscopy: eight years experience at Mayo clinic Rochester","volume":"56","author":"Hakim","year":"2011","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.bpg.2012.12.002_bib57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2005.01.013","article-title":"Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging","volume":"23","author":"Dromain","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bpg.2012.12.002_bib58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2214\/ajr.180.1.1800121","article-title":"MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques","volume":"180","author":"Dromain","year":"2003","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.bpg.2012.12.002_bib59","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/RLI.0b013e31823a1495","article-title":"Diagnostic accuracy and sensitivity of diffusion-weighted and of gadoxetic acid-enhanced 3-T MR imaging alone or in combination in the detection of small liver metastasis (<\/=\u00a01.5\u00a0cm in diameter)","volume":"47","author":"Kim","year":"2012","journal-title":"Invest Radiol"},{"issue":"5","key":"10.1016\/j.bpg.2012.12.002_bib60","first-page":"652","article-title":"Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide","volume":"33","author":"Krenning","year":"1992","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.bpg.2012.12.002_bib61","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.1365-2265.2003.01885.x","article-title":"SPECT\/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours","volume":"59","author":"Krausz","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1016\/j.bpg.2012.12.002_bib62","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1200\/JCO.2010.32.8559","article-title":"Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism?","volume":"29","author":"Reidy-Lagunes","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bpg.2012.12.002_bib63","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00259-007-0450-1","article-title":"Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours","volume":"34","author":"Buchmann","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.bpg.2012.12.002_bib64","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2007.15.1126","article-title":"Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography","volume":"26","author":"Koopmans","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bpg.2012.12.002_bib65","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.surg.2006.07.033","article-title":"Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival","volume":"140","author":"Givi","year":"2006","journal-title":"Surgery"},{"issue":"3","key":"10.1016\/j.bpg.2012.12.002_bib66","first-page":"263","article-title":"Neuroendocrine tumors of the ampulla of vater: presentation, pathology and prognosis","volume":"13","author":"Jayant","year":"2012","journal-title":"JOP"},{"issue":"24","key":"10.1016\/j.bpg.2012.12.002_bib67","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJM198312153092406","article-title":"Somatostatin","volume":"309","author":"Reichlin","year":"1983","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.bpg.2012.12.002_bib68","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1001\/jama.1985.03350420155035","article-title":"Somatostatin receptors","volume":"253","author":"Maurer","year":"1985","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.bpg.2012.12.002_bib69","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM199601253340408","article-title":"Octreotide","volume":"334","author":"Lamberts","year":"1996","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.bpg.2012.12.002_bib70","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue","volume":"315","author":"Kvols","year":"1986","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bpg.2012.12.002_bib71","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"O'Toole","year":"2000","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bpg.2012.12.002_bib72","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4","article-title":"Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group","volume":"77","author":"di Bartolomeo","year":"1996","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bpg.2012.12.002_bib73","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bpg.2012.12.002_bib74","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/gut.39.2.279","article-title":"Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients","volume":"39","author":"Ruszniewski","year":"1996","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.bpg.2012.12.002_bib75","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","article-title":"NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas","volume":"39","author":"Kulke","year":"2010","journal-title":"Pancreas"},{"issue":"6","key":"10.1016\/j.bpg.2012.12.002_bib76","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.bpg.2012.12.002_bib77","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.3748\/wjg.v16.i24.2963","article-title":"Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors","volume":"16","author":"Strosberg","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"12","key":"10.1016\/j.bpg.2012.12.002_bib78","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nrd1255","article-title":"Opportunities in somatostatin research: biological, chemical and therapeutic aspects","volume":"2","author":"Weckbecker","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.bpg.2012.12.002_bib79","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1005774713202","article-title":"Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action","volume":"15","author":"Woltering","year":"1997","journal-title":"Invest New Drugs"},{"issue":"4","key":"10.1016\/j.bpg.2012.12.002_bib80","first-page":"1816","article-title":"Octreotide inhibits insulin-like growth factor-I hepatic gene expression in the hypophysectomized rat: evidence for a direct and indirect mechanism of action","volume":"130","author":"Serri","year":"1992","journal-title":"Endocrinology"},{"issue":"28","key":"10.1016\/j.bpg.2012.12.002_bib81","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bpg.2012.12.002_bib82","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0016-5085(00)70143-0","article-title":"Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells","volume":"118","author":"Detjen","year":"2000","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bpg.2012.12.002_bib83","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198307213090301","article-title":"Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome","volume":"309","author":"Oberg","year":"1983","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bpg.2012.12.002_bib84","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/02841869309083916","article-title":"Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon","volume":"32","author":"Janson","year":"1993","journal-title":"Acta Oncol"},{"issue":"6","key":"10.1016\/j.bpg.2012.12.002_bib85","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bjs.4149","article-title":"Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours","volume":"90","author":"Kolby","year":"2003","journal-title":"Br J Surg"},{"issue":"14","key":"10.1016\/j.bpg.2012.12.002_bib86","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"Faiss","year":"2003","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bpg.2012.12.002_bib87","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2012.12.002_bib88","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/annonc\/mdi113","article-title":"mTOR-targeted therapy of cancer with rapamycin derivatives","volume":"16","author":"Vignot","year":"2005","journal-title":"Ann Oncol"},{"issue":"6021","key":"10.1016\/j.bpg.2012.12.002_bib89","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"issue":"9808","key":"10.1016\/j.bpg.2012.12.002_bib90","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bpg.2012.12.002_bib91","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-2559.1998.00321.x","article-title":"Expression of vascular endothelial growth factor in digestive neuroendocrine tumours","volume":"32","author":"Terris","year":"1998","journal-title":"Histopathology"},{"issue":"8","key":"10.1016\/j.bpg.2012.12.002_bib92","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2007.13.6374","article-title":"Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.bpg.2012.12.002_bib93","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","article-title":"Activity of sunitinib in patients with advanced neuroendocrine tumors","volume":"26","author":"Kulke","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15s","key":"10.1016\/j.bpg.2012.12.002_bib94","article-title":"A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide in advanced low-grade neuroendocrine carcinoma","volume":"28","author":"Phan","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bpg.2012.12.002_bib95","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","article-title":"Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors","volume":"24","author":"Kulke","year":"2006","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.bpg.2012.12.002_bib96","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2011.40.3147","article-title":"Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors","volume":"30","author":"Chan","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bpg.2012.12.002_bib97","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","article-title":"O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors","volume":"15","author":"Kulke","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2012.12.002_bib98","first-page":"62S","article-title":"Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs","volume":"46","author":"Kwekkeboom","year":"2005","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.bpg.2012.12.002_bib99","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","article-title":"Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience","volume":"32","author":"Valkema","year":"2002","journal-title":"Semin Nucl Med"},{"issue":"2","key":"10.1016\/j.bpg.2012.12.002_bib100","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.semnuclmed.2006.01.001","article-title":"Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors","volume":"36","author":"Valkema","year":"2006","journal-title":"Semin Nucl Med"},{"issue":"10","key":"10.1016\/j.bpg.2012.12.002_bib101","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","article-title":"90Y-edotreotide for metastatic carcinoid refractory to octreotide","volume":"28","author":"Bushnell","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bpg.2012.12.002_bib102","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bpg.2012.12.002_bib103","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J Am Coll Surg"},{"issue":"6","key":"10.1016\/j.bpg.2012.12.002_bib104","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.surg.2003.07.025","article-title":"Aggressive surgery for metastatic liver neuroendocrine tumors","volume":"134","author":"Norton","year":"2003","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.bpg.2012.12.002_bib105","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2214\/ajr.181.4.1811005","article-title":"Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes","volume":"181","author":"Henn","year":"2003","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"10.1016\/j.bpg.2012.12.002_bib106","first-page":"1091","article-title":"Cytoreductive hepatic surgery for neuroendocrine tumors","volume":"108","author":"McEntee","year":"1990","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.bpg.2012.12.002_bib107","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9610(99)80107-X","article-title":"Hepatic resection for metastatic neuroendocrine carcinomas","volume":"169","author":"Que","year":"1995","journal-title":"Am J Surg"},{"issue":"8","key":"10.1016\/j.bpg.2012.12.002_bib108","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1002\/1097-0142(19930415)71:8<2624::AID-CNCR2820710830>3.0.CO;2-B","article-title":"Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients","volume":"71","author":"Ruszniewski","year":"1993","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.bpg.2012.12.002_bib109","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2293::AID-CNCR8>3.0.CO;2-E","article-title":"Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors","volume":"83","author":"Eriksson","year":"1998","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bpg.2012.12.002_bib110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00130404-200307000-00008","article-title":"Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience","volume":"9","author":"Gupta","year":"2003","journal-title":"Cancer J"},{"issue":"1","key":"10.1016\/j.bpg.2012.12.002_bib111","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/107327480601300110","article-title":"Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors","volume":"13","author":"Strosberg","year":"2006","journal-title":"Cancer Control"},{"issue":"5","key":"10.1016\/j.bpg.2012.12.002_bib112","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.2214\/ajr.180.5.1801379","article-title":"Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results","volume":"180","author":"Loewe","year":"2003","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.1016\/j.bpg.2012.12.002_bib113","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1148\/radiology.189.2.7692465","article-title":"Transcatheter chemoembolization of progressive carcinoid liver metastasis","volume":"189","author":"Therasse","year":"1993","journal-title":"Radiology"},{"issue":"9","key":"10.1016\/j.bpg.2012.12.002_bib114","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1093\/annonc\/mdr614","article-title":"A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors","volume":"23","author":"Strosberg","year":"2012","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.bpg.2012.12.002_bib115","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/COC.0b013e31815e4557","article-title":"Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients","volume":"31","author":"Kennedy","year":"2008","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bpg.2012.12.002_bib116","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/SLA.0b013e3181728a45","article-title":"90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience","volume":"247","author":"Rhee","year":"2008","journal-title":"Ann Surg"},{"issue":"10","key":"10.1016\/j.bpg.2012.12.002_bib117","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/00007890-199811270-00007","article-title":"Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients","volume":"66","author":"Lehnert","year":"1998","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.bpg.2012.12.002_bib118","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1600-6143.2008.02233.x","article-title":"Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report","volume":"8","author":"Le Treut","year":"2008","journal-title":"Am J Transpl"}],"container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691813000279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691813000279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T01:43:24Z","timestamp":1595641404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691813000279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":118,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S1521691813000279"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2012.12.002","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroendocrine tumours of the small intestine","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2012.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}